bioserve
A REPROCELL COMPANY

MC-5293

Uncovering Mutations in Tumor DNA

& providing clinically actionable data for choice of the most optimal treatment



PULMOCARE+

There are two main categories of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC contributes a large proportion (approximately 85%) of lung cancers. With advances in genomic capabilities, personalized medicine brings new hope to people with lung cancer, especially NSCLC as it helps identify drugs that are likely to help in your treatment. Genetic testing is now becoming a routine part of diagnosis and staging for NSCLC patients. EGFR mutations occur in about 10 percent and KRAS mutation occur in about 25% people with NSCLC. Patients whose tumours do not have mutations in commonly associated lung cancer genes like EGFR or KRAS may have another abnormality called gene fusion. Most common example of this abnormality is fusion of ALK gene to other genes, most commonly EML4 forming ALK-EML4 fusion, a common abnormality detected in NSCLC patients.

WHY THIS TEST?

- Detection of genetic alterations which drives the growth of the tumor (Driver alterations) allows the selection of treatment regime for individual lung cancer patients.
- Sub-classify the type of cancer and accurate diagnosis
- Pulmocare+ panel contains guideline recommended genes with actionable targeted therapies.
- A single test to identify SNVs/ Indels/ Hotspots and Gene Fusions.
- Reporting contains up-to-date and relevant clinical trial information for the detected mutations/rearrangements, to simplify therapeutic decisions.

GENES (SNVS/ INDELS)	APPROVED THERAPY	GENES (FUSIONS)
ALK	Crizotinib,Ceritinib, Alectinib	ALK
RET	Cabozantinib, Vandetanib, Selpercatinib, Lpralsetinib Alectinib	RET
ROSl	Crizotinib, Cabozantinib, Entrectinib	ROS1
NTRK1	Entrectinib and Larotrectinib	NTRK1
BRAF	Vemurafenib, Dabrafenib plus Trametinib;	--
EGFR	Erlotinib, Gefitinib, Afatinib and Osimertinib	--
ERBB2	Aafatinib, Neratinib	--
MET	Crizotinib, Cabozantinib, TEPMETKO	--
PIK3CA	Pl3K inhibitors	--
KRAS	Sotorasib	--
NRAS	Trametinib	--
PTEN	PI3K-AKT inhibitors	--

METHOD

- This test uses targeted next-generation sequencing (NGS) to evaluate for SNVs/Indels in more than 20 genes associated with Lung Cancer
- ALK BRAF EGFR ERBB2 MET PIK3CA RET KRAS NRAS PTEN AKT1 MAP2K1 ROS1 TP53 STK11 KIT CDKN2A NTRK1 RUNX1 RB1 NF1
- Gene fusions in ALK, ROS, RET and NTRK

SAMPLE

- FFPE blocks

bioserve
A REPROCELL COMPANY

BIOSERVE BIOTECHNOLOGIES (INDIA) PVT LTD
Pinnacle Towers, 1st Floor, Plot No.9/17/A&B
Road No.6, IDA, Nacharam, Medchal-Malkagiri Dist.
Hyderabad-500076, Telangana

+91-40 2955 8178/8176
+91 912 122 9283
bioserve.india@reprocell.com
salesindia@reprocell.com
www.bioserve.in

REPROCELL

YOKOHANA - JAPAN | GLASGOW - UK
HYDERABAD - INDIA | BELTSVILLE - USA